LOGIN  |  REGISTER
Astria Therapeutics
Compass Therapeutics

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

May 09, 2024 | Last Trade: US$17.28 0.29 -1.65

SAN DIEGO / May 09, 2024 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences:

Citizens JMP Life Sciences Conference
Fireside Chat: Tuesday, May 14, 2024 at 1:30 p.m. Eastern Time in New York, NY

2024 RBC Capital Markets Global Healthcare Conference
Fireside Chat: Wednesday, May 15, 2024 at 11:30 a.m. Eastern Time in New York, NY

BofA Securities Health Care Conference
Fireside Chat: Wednesday, May 16, 2024 at 12:20 p.m. Eastern Time in Las Vegas, NV

Live webcasts of each fireside chat will be accessible on the company’s website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only FDA-approved drug for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and Twitter.

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page